
Dr. Schweizer on olaparib plus bipolar androgen therapy in mCRPC
“The activity that we saw with the combination was very promising and…it justifies additional clinical trials to determine whether or not this could have a place in terms of our standard treatment options for patients,” says Michael Schweizer, MD.
In this video, Michael Schweizer, MD, discusses the background, findings, and takeaways of the study, “
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


















